2026-04-13T18:02:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/106002024-06-06T08:38:44Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Harrison, Claire author McLornan, Donal author McMullin, Mary Frances author mesa, ruben author Palmer, Jeanne author Fox, Maria Laura author Gupta, Vikas author 2023-11-14T08:27:02Z 2023-11-14T08:27:02Z 2023-11 Patient-reported outcomes; Anemic; Myelofibrosis Resultados informados por los pacientes; Anémicos; Mielofibrosis Resultats informats pels pacients; Anèmics; Mielofibrosi Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that typically manifests with debilitating symptoms that progressively worsen, negatively impacting patients’ quality of life. Fatigue is a multifactorial and burdensome MF-related symptom due to its severity, persistence, and prevalence, with anemia a contributing factor and major unmet need. Clinical trials of the Janus kinase (JAK)1/JAK2/activin A receptor type 1 inhibitor momelotinib have shown consistent anemia benefits, in addition to improvements in MF-related symptoms. The phase 3 MOMENTUM trial in symptomatic and anemic patients met its primary end point, with a greater proportion having a Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score (TSS) reduction ≥50% at week 24 with momelotinib versus danazol. To support the positive primary end point result, we conducted longitudinal, responder, and time-to-event analyses of patient-reported outcomes from MOMENTUM, as measured by the MFSAF, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Patient-Reported Outcomes Measurement Information System (PROMIS) assessments. These analyses demonstrated rapid and durable response benefits with momelotinib, with achievement of first TSS response by day 29 and continued improvement over time. Improvements favored momelotinib versus danazol for each MFSAF individual item, and greater improvements were observed for disease- and cancer-related fatigue and physical functioning at week 24, with significant results for multiple items/domains across the 3 assessments. These findings are consistent in demonstrating that momelotinib provides substantial symptom benefit. This study was funded by Sierra Oncology, a GSK company. http://hdl.handle.net/11351/10600 Qualitat de vida Anèmia - Tractament Mielofibrosi - Tractament Medicaments antineoplàstics - Ús terapèutic DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos de neoplasias ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study